ArticleJournal of nephrology2015
Consequences of hemolytic uremic syndrome among hemodialysis patients.
Article in Journal of nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Clinical Impact of RSV Vaccination in Hemodialysis Patients: Real-World Evidence on Hospitalization Risk and the Role of Chronic Lung Disease.Advances in respiratory medicine · 2026Article
- Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data.Clinical nephrology · 2022Article
- A STARD-compliant prediction model for diagnosing thrombotic microangiopathies.Journal of nephrology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemolytic uremic syndrome (HUS) is characterized by hemolytic anemia, low platelets, and renal impairment and is mediated by thrombotic microangiopathy (TMA). A common perception is that HUS becomes dormant in dialysis patients with end-stage renal disease (ESRD). We analyzed patients in a large dialysis organization to understand the potential consequences and burden of HUS.
methodsWe identified patients with ESRD ascribed to HUS and those with ESRD ascribed to another cause (control patients) who received hemodialysis or peritoneal dialysis from 01 January 2007 to 31 December 2012. Outcomes were survival, hospitalization, and longitudinal laboratory values associated with TMA, including lactate dehydrogenase, red cell distribution width (RDW), platelets, and hemoglobin.
resultsHUS patients (n = 217) were propensity-score matched 1:5 to control patients (n = 1,085) for age, gender, race, dry weight, insurance, access, comorbidities, and Charlson comorbidity index. Compared to control patients, HUS patients had significantly greater risk for hospitalizations overall (RR = 2.3, p = 0.004) and hospitalization for hematologic (RR = 5.6, p = 0.001), cardiovascular (RR = 2.1, p = 0.02), and pancreatic (RR = 7.9, p = 0.04) causes. HUS patients also had evidence of ongoing TMA: higher lactate dehydrogenase and RDW, lower platelets and hemoglobin, and more frequent lactate dehydrogenase spikes.
conclusionsDialysis patients with HUS were at significantly higher risk than matched control patients for hospitalizations due to cardiovascular, hematologic, and pancreatic disease, which were associated with ongoing TMA. Additional studies are needed to determine whether targeted therapy for HUS reduces hospitalizations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.